Wed, November 27, 2024
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Brian Stokes
Trust Matters in Cabinet Picks
Mon, November 25, 2024
Sun, November 24, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Thu, April 23, 2009
Mon, February 2, 2009
[ Mon, Feb 02nd 2009 ] - Nathan Burkes
Is Obama a rock star?
Fri, January 30, 2009

Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New Yor


//health-fitness.news-articles.net/content/2012/ .. 012-global-healthcare-conference-in-new-yor.html
Published in Health and Fitness on Wednesday, May 30th 2012 at 12:46 GMT by Market Wire   Print publication without navigation


Nektar Therapeutics' President and CEO Howard W. Robin to Present at the... -- SAN FRANCISCO, May 30, 2012 /PRNewswire/ --

Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York

[ ]

SAN FRANCISCO, May 30, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: [ NKTR ]) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 5, 2012 at 11:30 a.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website [ http://www.nektar.com ]. This webcast will be available for replay until July 5, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at [ http://www.nektar.com ].

Nektar Investor Inquiries:


Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585

Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650



Nektar Media Inquiries:


Karen Bergman/BCC Partners

(650) 575-1509

SOURCE Nektar Therapeutics

[ Back to top ]

RELATED LINKS
[ http://www.nektar.com ]


Publication Contributing Sources